Check for updates

OPEN ACCESS

EDITED BY Spyridon N Karras, Aristotle University of Thessaloniki, Greece

REVIEWED BY Theocharis Koufakis, Aristotle University of Thessaloniki, Greece Yoshifumi Saisho, Saisho Diabetes Clinic, Japan

*CORRESPONDENCE Miao Yu yumiaoxh@163.com; yumiao@medmail.com.cn

SPECIALTY SECTION This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology

RECEIVED 03 May 2022 ACCEPTED 18 July 2022 PUBLISHED 09 August 2022

CITATION

Chai S, Zhang R, Zhang Y, Carr RD, Zheng Y, Rajpathak S and Yu M (2022) Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. *Front. Endocrinol.* 13:935039. doi: 10.3389/fendo.2022.935039

COPYRIGHT

© 2022 Chai, Zhang, Zhang, Carr, Zheng, Rajpathak and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A metaanalysis of randomized controlled trials

Shangyu Chai¹, Ruya Zhang¹, Ye Zhang¹, Richard David Carr², Yiman Zheng¹, Swapnil Rajpathak³ and Miao Yu⁴*

¹Merck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, China, ²Hatter Cardiovascular Institute, University College London, UK and Ulster University, Coleraine, United Kingdom, ³Merck & Co., Inc., Rahway, NJ, United States, ⁴Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

Objective: The influence of dipeptidyl peptidase-4 (DPP4) inhibitors on glycemic variability compared to other oral antidiabetic drugs (OADs), measured based on the mean amplitude of glycemic excursions (MAGE), has not been comprehensively analyzed. The aim of the study was to perform a meta-analysis to compare the effects of DPP4 inhibitors on MAGE with other OADs in type 2 diabetes mellitus (T2DM) patients without concurrent insulin treatments.

Methods: The Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library) databases were searched for relevant randomized controlled trials (RCTs). Study characteristics and outcome data were independently extracted by two authors. A random-effect model was used to combine the results.

Results: Fourteen studies with 855 patients were included. Compared to other OADs, DPP4 inhibitors significantly reduced MAGE (mean difference [MD]: -0.69 mmol/L, 95% confidence interval [CI]: -0.95 to -0.43, P<0.001) with mild heterogeneity ($I^2 = 28\%$). Predefined subgroup analyses suggested that DPP4 inhibitors were more effective in reducing MAGE compared to insulin secretagogues (MD: -0.92 mmol/L, P<0.001) and non-secretagogues (MD: -0.91 mmol/L, P<0.001) and sodium glucose cotransporter 2 inhibitors (MD: -0.67 mmol/L, P=0.03).

Conclusions: DPP4 inhibitors may significantly reduce glycemic variability compared to other oral anti-diabetic drugs, as evidenced by MAGE in T2DM patients with no concurrent insulin treatment.

Systematic review registration: INPLASY, registration number: INPLASY2021120113.

KEYWORDS

dipeptidyl peptidase-4 inhibitor, glycemic variability, mean amplitude of glycemic excursion, type 2 diabetes mellitus, meta-analysis

Introduction

Vascular complications are considered the main determinants for increased disability and mortality in patients with type 2 diabetes mellitus (T2DM) (1, 2). The major cause of vascular complication in T2DM patients is poor glycemic control and long-lasting hyperglycemia (3, 4). Interestingly, subsequent evidence showed that glycemic variability, which refers to multiple fluctuations of glycemia that occur throughout the day or over longer periods of time (5), may be another key factor that may accelerate the development of diabetic complications besides persistent hyperglycemia (6, 7). Indeed, epidemiological studies have suggested that increased glycemic variability is independently associated with the development of retinopathy, nephropathy, and possibly cardiovascular events and mortality in patients with T2DM (8-10). Experimental studies also confirmed that increased glycemic variability is associated with overactive oxidative stress and inflammatory responses (11, 12), which have been implicated in vascular complications in T2DM. Therefore, glycemic variability has been established as a novel treatment target for patients with T2DM.

Among the frequently used oral antidiabetic drugs (OADs), dipeptidyl-peptidase 4 (DPP4) inhibitors have shown promising therapeutic efficacy for T2DM patients on the basis of numerous benefits besides hypoglycemic efficacy such as the preservation of islet β -cell function (13), improvement of glycemic durability (14), and suppression of abnormal hyperglucagonaemia (15). Moreover, since increased glycemic variability is correlated with poor islet β -cell function (16), a beneficial effect of DPP4inhibitors on glycemic variability in T2DM patients has also been suggested in view of their beneficial effects on β -cell function (17). More importantly, the pharmacological mechanisms of DPP4 inhibitors involve enhancing incretin preservation, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby exerting their hypoglycemic effects *via* glucose-dependent insulin secretion and inhibiting glucagon production without increasing the risk of hypoglycemia (18, 19).

Conventionally, glycemic variability is evaluated based on the mean amplitude of glycemic excursions (MAGEs) via continuous glucose monitoring (CGM) or flash glucose monitoring (FGM) (20) and is also considered a reliable parameter for evaluating short-term within-day glycemic variability. Although some small-scale randomized controlled trials (RCTs) have been performed to compare the influences of DPP4 inhibitors and other OADs on MAGE in T2DM patients (21-34), the results of these RCTs were not consistent and a consensus on the efficacy of DPP4 inhibitors on glycemic variability compared to other OADs has not been fully determined. A previous meta-analysis (35) including only seven RCTs before 2018 showed that DPP4 inhibitors may be more effective than other OADs in reducing MAGE. However, some recently published eligible studies (30-34) have not been included in a meta-analysis. Accordingly, in this study, we aimed to perform an updated meta-analysis to summarize the current knowledge regarding the influence of DPP4 inhibitors on glycemic variability in comparison with other OADs. With more studies included, we also explored the potential influences of the study characteristics on the outcomes.

Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (36) and the Cochrane Handbook guidelines (37) were followed during the design and implementation of the study.

Data sources and searches

Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library) databases were searched for relevant studies with the following keywords: (1) "DPP4" OR "DPP-4" OR "dipeptidyl peptidase-4 inhibitors" OR "sitagliptin" OR

Abbreviations: T2DM, type 2 diabetes mellitus; DPP4, dipeptidyl-peptidase 4; GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide; FGM, flash glucose monitoring; RCT, randomized controlled trial; ADA, American Diabetes Association; CAD, coronary artery disease; CKD, chronic kidney disease; AMI, acute myocardial infarction; MACE, major adverse cardiovascular events; MAGE, mean amplitude of glycemic excursions.

"vildagliptin" OR "linagliptin" OR "saxagliptin" OR "alogliptin" OR "dutogliptin" OR "aemigliptin" OR "anagliptin" OR "teneligliptin" OR "trelagliptin" OR "omarigliptin" OR "gemigliptin" OR "evogliptin"; (2) "continuous glucose monitoring" OR "glycemic variability" OR "glyceamic variability" OR "glucose variability" OR "glyceamic variability" OR "glucose variability" OR "glycemic excursion" OR "MAGE" OR "mean amplitude of glycemic excursion" OR "MAGE" OR "standard deviation" OR "SDBG" OR "largest amplitude of glycemic excursion" OR "LAGE" OR "Coefficient of variation" OR "CV"; and (3) "random" OR "randomized" OR "randomised" OR "randomly". Only clinical studies were considered. The references of related reviews and original articles were also searched as a complement. The final database search was conducted on July 23, 2021.

Study selection

Studies that fulfilled the following criteria were included: (1) full-length articles published in English; (2) designed as parallelgroup or crossover RCTs; (3) included adult patients with T2DM who were not treated with insulin; (4) patients were allocated to a treatment group with DPP4 inhibitors or a control group with other OADs; and (5) reported the between-group difference of changes in MAGE using CGM or FGM from the baseline for patients in each arm of the study. Studies with drug-naïve patients or T2DM patients on background OAD therapy were included. Studies including T2DM patients with concurrent insulin therapy were excluded because the influence of insulin on blood glucose fluctuations is related to various factors such as dosage and categories, which may conceal the effect of combined OADs on blood glucose fluctuations. We did not consider studies including patients treated with single-dose/single-day DPP4 inhibitors because we did not plan to evaluate the acute effect of DPP4 inhibitors on glycemic variability. In addition, non-randomized studies, studies with non-T2DM patients, and those without MAGE measurement using CGM or FGM were excluded.

Data extraction and quality assessment

Database search, data extraction, and quality evaluation were conducted by two independent authors. Disagreements were resolved by discussion with the corresponding author. We extracted data regarding the study information (first author, publication year, and study country), study design (blind or open-label, crossover or parallel group), patient information (number of patients, mean age, sex, baseline HbA1c, and T2DM duration), details of background antidiabetic treatments, drugs and doses of DPP4 inhibitors and control OADs, treatment durations, and methods used for MAGE measurement. Quality evaluation was achieved using Cochrane's Risk of Bias Tool (37) according to the following aspects: (1) random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessors; (5) incomplete outcome data; (6) selective outcome reporting; and (7) other potential biases.

Data synthesis and analysis

The influences of DPP4 inhibitors on MAGE compared to controls in T2DM patients were presented as the mean difference (MD) and 95% confidence interval (CI). We used Cochrane's Q test to detect the heterogeneity (38). The I² statistic was also calculated, and an $I^2 > 50\%$ reflected significant heterogeneity (37). Pooled analyses were calculated using a random-effect model because this method incorporates the influence of potential heterogeneity and provides a more generalized result (37). Sensitivity analysis by excluding one study at a time was used to evaluate the influence of each study on the pooled results of the meta-analysis (37). Predefined subgroup analyses were performed to evaluate the potential influences of study characteristics on the outcome. Particularly, subgroup analysis was performed to explore the relative efficacy of DPP4 inhibitors on MAGE as compared with insulin secretagogues (sulphonylureas [SUs] and glinides) and non-secretagogues, as well as individual classes of OADs. Publication bias was evaluated by visual inspection of the funnel plots and Egger's regression asymmetry test results (39). P values < 0.05 were considered statistically significant. The RevMan (Version 5.1; Cochrane, Oxford, UK) software was applied for statistical analyses.

Results

Search results

The process of database search and study identification is shown in Figure 1. Briefly, 2,705 articles were obtained through the database search, and 1,905 were retrieved after the exclusion of duplicate records. Among them, 1,868 articles were subsequently excluded based on the titles and abstracts primarily because these studies were irrelevant to the aim of the meta-analysis. Of the 37 articles that underwent full-text review, 23 were further excluded for the reasons presented in Figure 1. Finally, 14 RCTs (21–34) were included.

Study characteristics and data quality

Table 1 shows the characteristics of the included studies.Overall, 14 RCTs comparing the effects of DPP4 inhibitors and



other OADs on MAGE in T2DM patients were included (21– 34). Since one study included two interventional groups with gemigliptin and sitagliptin, the two datasets were included in the meta-analysis independently. The studies included in the metaanalysis were published between 2013 and 2020. Three of them were crossover studies (21, 23, 32), while the others were parallel-group RCTs (22, 24–31, 33, 34). Various DPP4 inhibitors were used in these studies, such as vildagliptin, sitagliptin, linagliptin, and gemigliptin, and the control OADs included SUs, glinides, voglibose, pioglitazone, metformin, and dapagliflozin. The treatment durations varied between 5 and 168 days, and MAGE was measured using CGM or FGM for 24, 48, and 72 hours. The detailed quality evaluation for these studies is shown in Table 2, suggesting moderate study quality.

Comparisons between DPP4 inhibitors and other OADs on MAGE

Mild significant heterogeneity was detected among the included studies (P for Cochrane's Q test = 0.15, $I^2 = 28\%$). Pooled results showed that DPP4 inhibitors significantly reduced MAGE compared to other OADs in T2DM patients with no concurrent insulin treatment (MD: -0.69 mmol/L, 95% CI: -0.95 to -0.43, P<0.001; Figure 2A). Sensitivity analysis by excluding one dataset at a time did not significantly change the results (MD: -0.57 to -0.75 mmol/L, P all < 0.05). Specifically, the results remained consistent after excluding the only study with FGM (MD: -0.75 mmol/L, 95% CI: -1.03 to -0.46, P<0.001; $I^2 = 23\%$). Predefined subgroup analyses

suggested that DPP4 inhibitors were more effective at reducing MAGE compared to insulin secretagogues (MD: -0.92 mmol/L, 95% CI: -1.21 to -0.64, P < 0.001; $I^2 = 0\%$) and non-secret agogues (MD: -0.43 mmol/L, 95% CI: -0.79 to -0.07, P = 0.02; Figure 2B), as well as compared to sulfonylureas (MD: -0.91 mmol/L, 95% CI: -1.22 to -0.60, P < 0.001) and sodium glucose cotransporter 2 inhibitors ([SGLT-2] inhibitors, MD: -0.67 mmol/L, 95% CI: -1.27 to -0.08, P = 0.03, whereas the difference of MAGE between patients treated with DPP4 inhibitors and with glinides was not statistically significant (MD: -0.74 mmol/L, 95% CI: -2.11 to 0.62, P = 0.29; Figure 2C). In addition, subgroup analysis suggested that the reduction of MAGE was more remarkable in patients with T2DM duration \leq 5 years as compared to those with disease duration > 5 years, and in studies with 72 hours of glucose monitoring for MAGE measurement as compared to those with 24 or 48 hours (P for subgroup difference = 0.004 and 0.002, respectively; Table 3). Other study characteristics did not seem to significantly affect the results, such as the study design, patient number, age and sex of the patients, HbA1c at baseline, background therapy, treatment duration, or quality scores of the included RCTs (Table 3). Subgroup analyses comparing DPP4 inhibitors to metformin or voglibose were not performed because only one dataset available for these comparisons.

Publication bias

The funnel plots for the meta-analyses comparing the effects of DPP4 inhibitors and other OADs on MAGE were

Study	Country	Design	Patient number	Mean age	Male	Baseline HbA1c	T2DM dura- tion	Background treat- ment	Intervention	Control	Treatment dura- tion	MAGE measur- ing
				year	%	%	years				days	
(21)	USA	R, OL, CO	24	58.3	79.2	7.6	7	Metformin	Vildagliptin 50mg Bid	Glimepiride 2mg Qd	5	24h-CGM
(<mark>22</mark>)	Korea	R, DB	33	57.6	57.6	7.2	5.4	Metformin	Sitagliptin 100mg Qd	Glimepiride 2mg Qd	28	72h-CGM
(23)	Japan	R, CO	11	58	NR	7.3	8	Drug naïve	Sitagliptin 50mg Qd	Mitiglinide 10mg Tid	28	24h-CGM
(24)	Japan	R, OL	29	64.4	79.3	7	NR	Acarbose	Sitagliptin 50mg Qd	Mitiglinide 5-10mg Tid	28	72h-CGM
(25)	China	R	41	68.8	56.1	7.2	0	Metformin	Sitagliptin 100mg Qd	Glimepiride 1-4mg Qd	168	72h-CGM
(<mark>29</mark>)	Japan	R, SB	99	61.4	40.4	7.4	NR	Drug naïve	Linagliptin 5mg Qd	Voglibose 0.2mg Tid	84	24h-CGM
(28)	Korea	R, SB	31	49.4	71	9.6	0.8	Drug naïve	Gemigliptin 50 mg Qd	Glimepiride 2mg Qd	84	72h-CGM
(28)	Korea	R, SB	27	50.5	75	9.3	1.6	Drug naïve	Sitagliptin 100 mg Qd	Glimepiride 2mg Qd	84	72h-CGM
(22)	Korea	R, OL	25	56.4	52	7.3	NR	Metformin	Vildagliptin 50mg Bid	Pioglitazone 15mg Qd	112	72h-CGM
(22)	Korea	R, OL	34	56	58.8	7.6	6.1	Metformin	Vildagliptin 50mg Bid	Glimepiride 1-2mg Qd	84	48-h CGM
30)	Japan	R, OL	52	59.8	98.1	7.8	8.1	Drug naïve	Sitagliptin 50mg Qd	Glibenclamide 2.5 mg Qd	14	24h-CGM
(31)	Brazil	R, SB	37	61.9	0	7.3	NR	Metformin	Vildagliptin 50mg Bid	Gliclazide 60-120mg Qd	168	48-h CGM
(32)	Japan	R, CO	11	51.9	72.7	7.6	4.9	Metformin (750mg/d)	Linagliptin 5mg Qd	Metformin 500mg Tid	28	24h-CGM
(33)	Japan	R, SB	331	58.1	60.1	7.8	5.8	Drug naïve or metformin	Sitagliptin 50-100mg Qd	Dapagliflozin 5-10mg Qd	168	24h-FGM
(34)	Korea	R, SB	70	52	65.2	7 7.9	2.8	Drug naïve or metformin	Gemigliptin 50 mg Qd	Dapagliflozin 10mg Qd	84	72h-CGM

TABLE 1 Characteristics of the included RCTs.

RCTs, randomized controlled trials; HbA1c, glycated hemoglobulin; T2DM, type 2 diabetes mellitus; MAGE, mean amplitude of glycemic excursions; R, randomized; DB, double blind; SB, single blind; OL, open-label; CO, crossover; Qd, once daily; Bid, twice daily; Tid, three times per day; CGM, continuous glucose monitoring; FGM, flash glucose monitoring.

TABLE 2 Details of study quality evaluation via the Cochrane's Risk of Bias Tool.

Study	Randomsequencegeneration	Allocationconcealment	Blinding of participants	Blinding of outcome assessment	Incomplete outcome data addressed	Selectivereporting	Other sources of bias
(21)	Unclear	Unclear	High	High	Low	Low	Low
(22)	Unclear	Unclear	Low	Low	Low	Low	Low
(23)	Unclear	Unclear	Unclear	Unclear	Low	Low	Low
(24)	Unclear	Low	High	High	Low	Low	Low
(25)	Unclear	Unclear	Unclear	Unclear	Low	Low	Low
(29)	Unclear	Unclear	Unclear	Low	Low	Low	Low
(28-	Unclear	Low	High	Low	Low	Low	Low
(28)	Unclear	Low	High	Low	Low	Low	Low
(<mark>26</mark>)	Unclear	Unclear	High	High	Low	Low	Low
(27)	Unclear	Unclear	High	High	Low	Low	Low
(<mark>30</mark>)	Unclear	Unclear	High	High	Low	Low	Low
(31)	Unclear	Unclear	High	Low	Low	Low	Low
(32)	Unclear	Unclear	High	High	Low	Low	Low
(33)	Low	Unclear	High	Low	Low	Low	Low
(34)	Unclear	Unclear	High	Low	Low	Low	Low

A		DPP4	inhibit	ors	Othe	er OAD	s		Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV. Random. 95% CI	
	He 2013	3.24	1.47	24	3.83	1.47	24	7.1%	-0.59 [-1.42, 0.24]		
	Kim 2013	-1.2	0.94	16	-0.7	1.45	17	7.1%	-0.50 [-1.33, 0.33]		
	Ando 2014 Osopoi 2014	4.83	2.19	11	4.63	1.99	11	2.0%	0.20 [-1.55, 1.95]		
	Xiao 2016	-3.64	1.01	23	-2.26	0.84	18	11.7%	-1.38 [-1.95, -0.81]		
	Satoh 2017	-1.35	1.89	47	-1.31	1.9	52	8.3%	-0.04 [-0.79, 0.71]		
	Park 2017-gem	-2.33	1.83	23	-1.17	1.28	9	4.4%	-1.16 [-2.28, -0.04]		
	Park 2017-sit	-2.33	1.61	19	-1.17	1.28	9	4.6%	-1.16 [-2.27, -0.05]		
	Kim 2017a Kim 2017b	-1.28	1.56	14	-1.33	1.6	17	3.7% 4.6%	-1.01 [-2.11, 0.09]		
	Suzuki 2018	-1.02	1.64	26	-0.54	1.63	26	6.4%	-0.48 [-1.37, 0.41]		
	Vianna 2018	-1.4	2.1	19	-1.2	2.3	18	3.0%	-0.20 [-1.62, 1.22]		
	Takahashi 2019	5.67	1.75	11	5.62	1.96	11	2.5%	0.05 [-1.50, 1.60]		-
	Fuchigami 2020 Kwak 2020	-1.27	1.54	34	-0.83	1.59	36	8.8%	-0.44 [-0.78, -0.10] -1.07 [-1.79, -0.35]		
								01070			mmol/l
	Total (95% CI) Heterogeneity: Tau ² =	0.07; Cł	i ² = 19.4	461 18, df =	: 14 (P =	= 0.15)	442 ² = 28	100.0% 3%	-0.69 [-0.95, -0.43]	-2 -1 0 1	
	l est for overall effect:	Z = 5.22	(P < 0.0	0001)					Fa	vours DPP4 inhibitors Favours con	rols
в		DPP4	inhibit	ors	Othe	er OAD	s		Mean Difference	Mean Difference	
	Study or Subgroup 1.2.1 Insulin secretag	Mean gogues	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV. Random, 95% Cl	
	He 2013	3.24	1.47	24	3.83	1.47	24	7.1%	-0.59 [-1.42, 0.24]	+	
	Kim 2013	-1.2	0.94	16	-0.7	1.45	17	7.1%	-0.50 [-1.33, 0.33]		
	Ando 2014 Osopoi 2014	4.83	2.19	11	4.63	1.99	11	2.0%	0.20 [-1.55, 1.95]	[
	Xiao 2016	-3.64	1.01	23	-2.26	0.84	18	11.7%	-1.38 [-1.95, -0.81]		
	Park 2017-gem	-2.33	1.83	23	-1.17	1.28	9	4.4%	-1.16 [-2.28, -0.04]		
	Park 2017-sit	-2.33	1.61	19	-1.17	1.28	9	4.6%	-1.16 [-2.27, -0.05]		
	Kim 2017b Suzuki 2018	-1.32	1.78	17	-0.31	1.47	17	4.6%	-1.01 [-2.11, 0.09]		
	Vianna 2018	-1.02	2.1	20 19	-0.54	2.3	20 18	3.0%	-0.20 [-1.62, 1.22]		
	Subtotal (95% CI)			192			164	58.4%	-0.92 [-1.21, -0.64]	◆	
	Heterogeneity: Tau ² = Test for overall effect:	0.00; Ch Z = 6.29	i ² = 8.68 (P < 0.0	3, df = 00001)	9 (P = 0	.47); I²	= 0%				
	1.2.2 Non-secretagog	gues									
	Satoh 2017	-1.35	1.89	47	-1.31	1.9	52	8.3%	-0.04 [-0.79, 0.71]		
	Kim 2017a	-1.28	1.56	14	-1.33	1.6	11	3.7%	0.05 [-1.20, 1.30]		
	Fuchigami 2019	-1 27	1.75	11	5.62 -0.83	1.96	11	2.5%	-0.44 [-0.78 -0.10]		
	r donigarni zozo	-1.51	4.40	100	-0.00	1.00	100	10.070	0.441 0.70. 0.101		
	Kwak 2020	-1.51	1.42	34	-0.44	1.63	36	8.8%	-1.07 [-1.79, -0.35]		
	Subtotal (95% CI)	-1.51	1.42	34 269	-0.44	1.63	36 278	8.8% 41.6%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07]		
	Kwak 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect:	0.04; Ch Z = 2.35	1.42 ii ² = 5.06 (P = 0.0	34 269 6, df = 02)	-0.44 4 (P = 0	1.63 .28); l²	36 278 = 21%	8.8% 41.6%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07]	•	
	Kwak 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI)	0.04; Cł Z = 2.35	1.42 ii ² = 5.06 (P = 0.0	34 269 5, df = 02) 461	-0.44 4 (P = 0	1.63 .28); I ²	36 278 = 21% 442	8.8% 41.6%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43]	•	mmol/L
	Kwak 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:	0.04; CH Z = 2.35 0.07; CH Z = 5.22	$i^{2} = 5.06$ (P = 0.0 $i^{2} = 19.4$ (P < 0.0	34 269 5, df =)2) 461 48, df =)0001)	-0.44 4 (P = 0 : 14 (P =	1.63 .28); I² = 0.15)	36 278 = 21% 442 I ² = 28	8.8% 41.6% 100.0% 3%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa	→ → → → → → → → → → → → → →	mmol/L 2 rols
C	Kwak 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe	0.04; Cr Z = 2.35 0.07; Cr Z = 5.22 erences:	1.42 (P = 0.0 (P = 0.0 (P = 0.0 (P < 0.0 Chi ² = 4	34 269 3, df = 22) 461 48, df = 00001) .46. df	-0.44 4 (P = 0 : 14 (P = = 1 (P =	1.63 .28); I ² = 0.15) = 0.03).	36 278 = 21% 442 ² = 28	8.8% 41.6% 100.0% 3% 7.6%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa	-2 -1 0 1 vours DPP4 inhibitors Favours con	mmol/L 2 rols
с	Kwak 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Test for subaroun diffe Study or Subgroup	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 erences: DPP4 Mean	1.42 $i^2 = 5.06$ (P = 0.0) $i^2 = 19.2$ (P < 0.0) $Chi^2 = 4$ inhibite <u>SD</u>	34 269 3, df = 22) 461 48, df = 00001) .46. df ors Total	-0.44 4 (P = 0 = 14 (P = = 1 (P = Othe <u>Mean</u>	1.63 .28); I ² = 0.15); = 0.03); = 0AE SD	36 278 = 21% 442 ² = 28 ² = 77 s Total	8.8% 41.6% 100.0% 3% 7.6% Weight	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random. 95% CI	-2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L 2 rols
с	Kwak 2020 Subbtal (85% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.3.1 SU	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 erences: DPP4	1.42 $i^2 = 5.06$ (P = 0.0) $i^2 = 19.4$ (P < 0.0) (P < 0.0) $Chi^2 = 4$ inhibit	34 269 5, df = 02) 461 48, df = 00001) .46. df ors Total	-0.44 4 (P = 0 = 14 (P = = 1 (P = Othe <u>Mean</u>	1.63 .28); I ² = 0.15); = 0.03); = 0.03); = 0.03); = 0.03);	36 278 = 21% 442 ² = 28 ² = 77 s Total	8.8% 41.6% 100.0% 3% 7.6% <u>Weight</u>	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random. 95% Cl	-2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L 2 rols
с	Kwak 2020 Subbtal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Test for subgroup 1.3.1 SU He 2013 Vim 2012	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 erences: DPP4 Mean 3.24	1.42 $i^2 = 5.06$ (P = 0.0) $i^2 = 19.4$ (P < 0.0) Chi ² = 4 inhibit <u>SD</u> 1.47 0.24	34 269 5, df = 02) 461 48, df = 00001) .46. df ors <u>Total</u> 24	-0.44 4 (P = 0 : 14 (P = = 1 (P = Othe <u>Mean</u> 3.83	1.63 .28); I ² = 0.15); = 0.03); = 0.03); = 0.03); = 0.03); = 0.04; = 0.04; = 0.04; = 0.04; = 0.04; = 0.15; =	36 278 = 21% 442 $ ^2 = 28$ $ ^2 = 77$ $ ^2 = 10^{10}$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] 0.50 [-4.20, 0.24]	-2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L 2 rols
с	Kwak 2020 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Kim 2013	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 erences: DPP4 Mean 3.24 -1.2 -3.64	1.42 $i^2 = 5.06$ (P = 0.0) $i^2 = 19.4$ (P < 0.0) Chi ² = 4 inhibit <u>SD</u> 1.47 0.94 1.01	34 269 3, df = 02) 461 48, df = 00001) .46. df ors Total 24 16 23	-0.44 4 (P = 0 = 14 (P = = 1 (P = Othe <u>Mean</u> 3.83 -0.7 -2.26	1.63 .28); I ² = 0.15) = 0.03). = 0.03). = 0.03). = 0.03). = 1.47 1.45 0.84	36 278 = 21% 442 ² = 28 ² = 77 s Total 24 17 18	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 8.0% 14.0%	-1.07 [-1.76, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random. 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81]	-2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L + rols
с	Kwak 2020 Subbtai (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Test for subaroun diffe <u>Study or Subgroup</u> 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gem	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 erences: DPP4 	1.42 $i^2 = 5.06$ (P = 0.0) $i^2 = 19.4$ (P < 0.0) Chi ² = 4 inhibit <u>SD</u> 1.47 0.94 1.01 1.83	34 269 5, df = - ()2) 461 48, df = ()0001) .46. df ors Total 24 16 23 23	-0.44 4 (P = 0 = 14 (P = = 1 (P = 0the Mean 3.83 -0.7 -2.26 -1.17	1.63 .28); I ² = 0.15) = 0.03). = 0.03). = 0.03). = 0.03). = 0.03). = 0.03). = 1.47 1.45 0.84 1.28	36 278 = 21% 442 ² = 28 ² = 75 s Total 24 17 18 9	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 8.0% 14.0% 4.8%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random. 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.8, 0.04]	-2 -1 0 1 -2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L + rols
с	Kwak 2020 Subbtal (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subarouo diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gem Park 2017-sit	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 erences: DPP4 Mean 3.24 -1.2 -3.64 -2.33 -2.33	1.42 $i^2 = 5.06$ (P = 0.0) $i^2 = 19.4$ (P < 0.0) Chi ² = 4 inhibit 1.47 0.94 1.01 1.83 1.61	34 269 5, df =)2) 461 48, df =)0001) .46. df 0005 Total 24 16 23 23 19	-0.44 4 (P = 0 = 14 (P = = 1 (P = 0the Mean 3.83 -0.7 -2.26 -1.17 -1.17	1.63 .28); I ² = 0.15); = 0.03); = 0.03); = 0.03); = 0.03); = 0.03); = 0.03); = 0.15); = 0.15]; = 0.1	36 278 = 21% 442 ² = 28 ² = 7 s Total 24 17 18 9 9	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 14.0% 14.0% 4.8% 4.9%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random. 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.27, -0.05]	-2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L + 2 rols
С	Kwak 2020 Subbtal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: Test for subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-sit Kim 2017-bit Kim 2017-bit	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 rences: DPP4 Mean 3.24 -1.2 -3.64 -2.33 -2.33 -1.32	1.42 $i^2 = 5.06$ (P = 0.0) $i^2 = 19.4$ (P < 0.0) Chi ² = 4 inhibit 5D 1.47 0.94 1.01 1.83 1.61 1.78 1.61	34 269 5, df = -)2) 461 18, df =)00001) .46. df 0005 Total 24 16 23 23 19 17 20	-0.44 4 (P = 0 = 1 (P = 0the Mean 3.83 -0.7 -2.26 -1.17 -1.17 -0.51	1.63 .28); ² = 0.15) = 0.03) or OAE SD 1.47 1.45 0.84 1.28 1.28 1.47	$36 \\ 278 \\ = 21\%$ $442 \\ 2 = 2! \\ 2 = 7;$ is Total $24 \\ 17 \\ 18 \\ 9 \\ 9 \\ 17 \\ 26$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 14.0% 4.8% 4.9% 5.0% 7.2%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV, Random, 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.04 [-1.07, -0.14]	-2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L 2 rols
С	Kwak 2020 Subbtai (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gem Park 2017-gem Park 2017-bit Kim 2017b Suzuki 2018	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 rences: DPP4 Mean 3.24 -1.2 -3.64 -2.33 -2.33 -1.32 -1.02 -1.4	1.42 $ii^2 = 5.06$ (P = 0.0) $ii^2 = 19.4$ (P < 0.0) Chi ² = 4 inhibit SD 1.47 0.94 1.01 1.83 1.61 1.78 1.64 2.1	34 269 3, df = -)2) 461 48, df = 00001) .46. df 0005 Total 24 16 23 23 19 17 26 19	-0.44 4 (P = 0 = 1 (P = 0the Mean 3.83 -0.7 -2.26 -1.17 -1.17 -0.34 -0.34 -1.2	1.63 .28); ² = 0.15) = 0.03) = 0	$36 \\ 278 \\ = 21\% \\ 442 \\ ^2 = 21\% \\ ^2 = 77 \\ 1s \\ Total \\ 24 \\ 17 \\ 18 \\ 9 \\ 9 \\ 17 \\ 18 \\ 9 \\ 9 \\ 17 \\ 16 \\ 18 \\ 18 \\ 18 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 8.0% 14.0% 4.8% 5.0% 7.2% 3.1%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.82, 1.22]	Active constraints of the second seco	mmol/L 2 rols
с	Kwak 2020 Subbtai (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gem Park 2017-sit Kim 2017b Suzuki 2018 Vianna 2018 Suzuki 2018 Vianna 2018	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 Prences: DPP4 Mean 3.24 -1.2 -3.64 -2.33 -1.32 -1.02 -1.4	1.42 $ii^2 = 5.06$ (P = 0.0) $ii^2 = 19.4$ (P < 0.0) Chi ² = 4 inhibit <u>SD</u> 1.47 0.94 1.01 1.83 1.61 1.78 1.64 2.1	34 269 5, df = -)2) 461 48, df = 00001) .46. df 0005 Total 24 16 23 23 19 17 26 19 17 26	-0.44 4 (P = 0 = 1 (P = 0the Mean 3.83 -0.7 -2.26 -1.17 -1.17 -0.31 -0.54 -1.2	1.63 .28); ² = 0.15) = 0.03). = 0.030. = 0.030.	$36 \\ 278 \\ = 21\% \\ 442 \\ 2 = 21\% \\ 2 = 77 \\ is \\ Total \\ 17 \\ 18 \\ 9 \\ 9 \\ 17 \\ 18 \\ 9 \\ 17 \\ 18 \\ 138 \\ 1$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 8.0% 14.0% 4.8% 5.0% 7.2% 3.1%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random .95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.16 [-2.28, -0.04] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.62, 1.22] -0.91 [-1.22, -0.60]	-2 -1 0 1 -2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L 2 rols
с	Kwak 2020 Subbtai (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Test for overall effect: Test for suborou diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-b Suzuki 2018 Subbtai (95% Cl) Heterogeneily: Tau ² = Test for overall effect:	0.04; Cł Z = 2.35 0.07; Cł Z = 5.22 orences: DPP4 Mean 3.24 -1.2 -3.64 -2.33 -2.33 -1.32 -1.02 -1.4 0.00; Cł Z = 5.70	$\begin{array}{l} {}_{1,42}\\ {}_{12}=5.06\\ (P=0.)\\ {}_{12}=19.0\\ (P<0.)\\ (P<0.)\\ Chi^2=4\\ {}_{10}\\ {}_{1$	34 269 3, df = -)2) 461 48, df = 00001) .4.6. df ors Total 24 16 23 23 19 17 26 19 17 26 19 17 26 3, df = -)0001)	-0.44 4 (P = 0 14 (P = 0 14 (P = 0 14 (P = 0 14 (P = 1 14 (P = 1)))))))))))))))))))))))))))))))))))	1.63 .28); ² = 0.15) = 0.03). or OAE SD 1.47 1.45 0.84 1.28 1.28 1.28 1.47 1.63 2.3 .49); ²	$36 \\ 278 \\ 278 \\ = 21\% \\ 442 \\ ^2 = 21 \\ ^2 = 7.5 \\ \hline Total \\ 17 \\ 18 \\ 9 \\ 9 \\ 17 \\ 26 \\ 18 \\ 138 \\ = 0\% \\ \hline$	8.8% 41.6% 41.6% 3% 7.6% 8.0% 8.0% 14.0% 4.8% 5.0% 7.2% 3.1% 55.1%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.62, 1.22] -0.91 [-1.22, -0.60]	A constraints of the second se	mmol/L 2 rols
С	Kwak 2020 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for suboroup 1.3.1 SU He 2013 Kim 2013 Kim 2013 Kim 2013 Kim 2016 Park 2017-sit Kim 2017b Suzuki 2016 Park 2017-sit Kim 2017b Suzuki 2018 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.3.2 Glinide	0.04; Ch Z = 2.35 0.07; Ct Z = 5.22 rences: DPP4 <u>Mean</u> 3.24 -1.2 -3.64 -2.33 -1.32 -1.32 -1.32 -1.32 -1.40 0.00; Ct Z = 5.70	$i^{2} = 5.0 \epsilon$ $i^{2} = 19.2 \epsilon$ $i^{2} = 19.$	34 34 269 5, df = - 3, df = - 461 188, df = 00001) 4.46. df 00001) 4.46. df 00001) 7 24 16 23 23 19 17 26 19 17 26 19 167 3, df = - 9, df = - 00001)	-0.44 4 (P = 0 = 1 (P = 0 the Mean 3.83 -0.7 -2.26 -1.17 -0.31 -0.54 -1.2 7 (P = 0	1.63 .28); ² = 0.15) = 0.03) = 0.03) = 0.03) = 0.03) .47 1.45 0.84 1.28 1.28 1.28 1.47 1.63 2.3 .49); ²	$\begin{array}{c} 36\\ 278\\ 278\\ 442\\ 1^2=21\\ 1^2=21\\ 1^2=7\\ 7\\ 7\\ 7\\ 7\\ 18\\ 9\\ 9\\ 17\\ 26\\ 18\\ 138\\ 38\\ \mathbf{=0\%} \end{array}$	8.8% 41.6% 41.6% 3% 7.6% 8.0% 8.0% 14.0% 4.8% 4.9% 5.0% 3.1% 55.1%	-1.07 [-1.70, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV, Random, 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.62, 1.22] -0.91 [-1.22, -0.60]	-2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L + 2 rols
С	Kwak 2020 Subbtai (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Test for overall effect: Test for subaround diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-sit Kim 2016 Subtotal (95% Cl) Heterogeneily: Tau ² = Test for overall effect 1.3.2 Glinide Ando 2014	0.04; Cr Z = 2.35 0.07; Cr Z = 5.22 prences: pPP4 <u>Mean</u> 3.24 -1.2 -3.64 -2.33 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.34 -1.22 -3.64 -1.22 -1.32 -1.34 -1.22 -1.34 -1.34 -1.32 -1.32 -1.32 -1.34 -1.32 -1.32 -1.34 -1.22 -1.34	1.42 i ² = 5.06 (P = 0.0 (P < 0.0 Chi ² = 4 inhibit SD 1.47 0.94 1.01 1.63 1.64 2.11 i ² = 6.43 (P < 0.0 2.19	34 34 269 5, df = . 22) 461 18, df = 00001) 4.46. df 00001) 4.46. df 00001) 24 16 23 23 19 167 3, df = 100001) 11	-0.44 4 (P = 0 + 14 (P = 0 + 14 (P = 0 - 1 (P = 0) - 2 (P	1.63 .28); ² = 0.15) = 0.03) = 0.03) = 0.03) = 0.03) .47 1.45 0.84 1.28 1.28 1.28 1.47 1.63 2.3 .49); ²	$\begin{array}{c} 36\\ 278\\ 278\\ 278\\ 12\\ 12\\ 12\\ 24\\ 17\\ 17\\ 18\\ 9\\ 9\\ 17\\ 18\\ 138\\ 138\\ 138\\ 138\\ 138\\ 138\\ 138\\$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 8.0% 14.0% 4.8% 5.0% 7.2% 3.1% 55.1%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random <u>95% C1</u> -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.62, 1.22] -0.91 [-1.22, -0.60]	-2 -1 0 1 -2 -1 0 1 vours DPP4 inhibitors Favours con Mean Difference IV. Random. 95% Cl	mmol/L 2 rols
С	Kwak 2020 Subbtai (95% CI) Heterogeneily: Tau ² = Test for overall effect: Total (95% CI) Heterogeneily: Tau ² = Test for overall effect: Test for suboroun diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2018 Subbtai (95% CI) Heterogeneily: Tau ² = Test for overall effect: 1.3.2 Glinide Ando 2014 Osonoi 2014	0.04; Cr Z = 2.35 0.07; Cr Z = 5.22 0.07; Cr Z = 5.22 0.07; Cr Z = 5.22 0.07; Cr Z = 5.22 0.07; Cr 2 = 5.20 0.07; Cr 2 = 5.22 0.07; Cr 2 = 5.20 0.07; Cr 2 = 5.70 0.07; Cr 2 = 5.70; Cr 2 = 5.70; Cr 2 = 5.70; Cr 2 = 5.70; Cr 2 = 5	$i^{2} = 5.0 \varepsilon (P = 0.C)$ $i^{2} = 19$ $i^{2} = 19$ $i^{2} = 19$ $i^{2} = 19$ $i^{2} = 10$ $i^{2} = 10$ $i^{2} = 6.43$ $(P < 0$ 2.19 1.21	34 34 269 35, df = .)22) 461 188, df = 00001) .46. df 0005 Total 24 166 23 19 17 266 23 19 17 266 19 17 266 19 167 23, df = . 17 26 20 24 16 24 25 24 24 25 24 24 25 24 24 24 24 24 24 24 24 24 24 24 24 24	-0.44 4 (P = 0 + 14 (P = 0 	1.63 .28); ² = 0.15) = 0.03) ar OAE SD 1.47 1.45 1.28 1.28 1.28 1.28 1.23 .49); ² 1.99 1	$\begin{array}{c} 36\\ 278\\ 278\\ 278\\ 278\\ 442\\ 1^2=21\\ 1^2=21\\ 1^2=7\\ 18\\ 9\\ 9\\ 17\\ 18\\ 138\\ 9\\ 9\\ 17\\ 26\\ 18\\ 138\\ 138\\ =0\%\\ 11\\ 15\\ 26\\ 26\\ 12\\ 26\\ 11\\ 15\\ 26\\ 12\\ 26\\ 11\\ 15\\ 26\\ 12\\ 26\\ 12\\ 26\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12$	8.8% 41.6% 100.0% 7.6% Weight 8.0% 14.0% 5.0% 5.5.1% 2.1% 8.3%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.03] -0.48 [-1.37, 0.41] -0.20 [-1.52, 1.22] -0.91 [-1.22, -0.60] 0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45]	Mean Difference IV. Random. 95% Cl	mmol/L +2 rols
С	Kwak 2020 Subbtai (95% CI) Heterogeneily: Tau ² = Test for overall effect: Test for overall effect: Test for suborou diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gen Park 2017-gen Park 2017-gen Park 2017-gen Park 2017-gen Park 2017-gen Park 2017-gen Park 2017-gen Park 2017-gen Park 2018 Subtotal (95% CI) Heterogeneily: Tau ² = Test for overall effect: 1.3.2 Glinide Ando 2014 Subtotal (95% CI) Heterogeneily: Tau ² = Test for overall effect:	0.04; Cf Z = 2.35 0.07; Cf Z = 5.22 rences: DPP4 -1.2 -1.2 -1.3 -1.32 -1.32 -1.32 -1.32 -1.32 -1.4 0.00; Cf Z = 5.70 -1.54 0.58; Cf Z = 1.07	$i^{2} = 5.06$ $i^{2} = 19.4$ (P = 0.0) (P = 0.0) (P = 0.0) (P = 0.0) (P = 0.0) (P < 0.0) 1.01 1.83 1.61 1.77 0.94 1.01 1.83 1.61 1.78 1.64 2.19 1.21 $i^{2} = 6.43$ (P < 0.0) 1.21 $i^{2} = 2.2(0)$ (P = 0.0) (P = 0.0) (P < 0.0) (P = 0.0) (P	34 34 269 3, df =-)2) 461 48, df = 00001) 1,46. df ors Total 24 16 16 23 23 23 19 7 26 19 19 7 3, df = 19 19 7 3, df =- 11 14 20 20 20 20 20 20 20 20 20 20 20 20 20	-0.44 4 (P = 0 1 14 (P = 0 1 (P = 1 (P = 1(P =	1.63 .28); ² = 0.15) = 0.03). er OALE SD 1.47 1.45 1.28 1.28 1.27 1.63 2.3 .49); ² 1.99 1 .14); ²	$\begin{array}{c} 36\\ 278\\ 278\\ \mathbf{=}21\%\\ 442\\ \mathbf{ ^{2}=21}\\ \mathbf{ ^{2}=7}\\ 5\\ \mathbf{Total}\\ 24\\ 177\\ 18\\ 99\\ 97\\ 17\\ 18\\ 188\\ 99\\ 97\\ 17\\ 188\\ 388\\ \mathbf{=0\%}\\ 11\\ 15\\ 26\\ \mathbf{e}=55\%\\ \end{array}$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 8.0% 7.2% 5.0% 7.2% 5.0% 7.2% 5.0% 7.2%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random .95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -0.20 [-1.55, 1.95] -0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62]	Mean Difference IV. Random. 95% Cl	mmol/L 2 Trols
с	Kwak 2020 Subbtai (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Test for overall effect: Test for subcroup diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gen Park 2014-gen Park	0.04; Cf Z = 2.35 0.07; Cf Z = 5.22 rences: DPP4 <u>Mean</u> 3.24 -1.2 -3.64 -2.33 -3.64 -2.33 -1.32 -1.02 -1.4 0.00; Cf Z = 5.70 4.83 -1.54 0.58; Cf Z = 1.07 rs	$\begin{array}{l} 1.42\\ i^2=5.06\\ (P=0.)\\ i^2=19.2\\ (P<0.)\\ (P<0.0Chi^2=4\\ inhibit\\ SD\\ 0.94\\ 1.01\\ 1.83\\ 1.61\\ 1.78\\ 1.61\\ 1.78\\ 1.61\\ 2.19\\ 1.21\\ i^2=6.43\\ (P<0.028\\ 1.21\\$	34 34 269 269 220 461 48, df = 00001) 1.46. df ors Total 24 16 23 23 23 19 17 26 6 19 167 3, df = 10001) 167 3, df = 29)	-0.44 4 (P = 0 = 1 (P = 0the Mean -0.7 -2.26 -1.17 -0.31 -0.54 -1.2 7 (P = 0 4.63 -0.28 1 (P = 0	1.63 .28); ² = 0.15) = 0.03) or OAL SD 1.47 1.45 0.84 1.28 1.47 1.63 2.3 .49); ² 1.99 1 .14); ²	$\begin{array}{r} 36\\ 278\\ =218\\ \mathbf{i}^2=21\\ \mathbf{i}^2=22\\ \mathbf{i}^2=7\\ \mathbf{i}^3\\ \mathbf{Total}\\ 17\\ 26\\ 18\\ 9\\ 9\\ 17\\ 26\\ 18\\ 8\\ =0\\ 11\\ 15\\ 26\\ 26\\ =55\% \end{array}$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 8.0% 7.2% 5.5.1% 2.1% 10.4%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random. 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.62, 1.22] -0.91 [-1.22, -0.60] 0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62]	Mean Difference IV. Random. 95% Cl	mmol/L +2 rols
с	Kwak 2020 Subbtai (95% CI) Heterogeneily: Tau ² = Test for overall effect: Total (95% CI) Heterogeneily: Tau ² = Test for overall effect: Test for suboroun diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Xiao 2016 Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-gem Park 2018 Subtotal (95% CI) Heterogeneily: Tau ² = Test for overall effect: 1.3.3 SGLT2 inhibitor Fuchigami 2020	0.04; Cf Z = 2.35 0.07; Cf Z = 5.222 rerences: DPP4 Mean 3.24 -1.2 -3.64 -2.33 -1.32 -1.42 0.00; Cf Z = 5.70 -1.4 0.00; Cf Z = 5.70 -1.4 0.05; Cf Z = 1.07 -75 -1.54 -1.	$\begin{array}{c} 1.42\\ i^2=5.00\\ (P=0.)\\ (P=0.)\\ (P<0.)\\ (P<0.)\\ (P<0.)\\ (P<0.)\\ (P<0.)\\ (P<0.)\\ 1.01\\ 1.0$	34 269 269 22) 461 18, df = 20 0001) .46. df ors Total 24 16 23 19 167 26 19 19 167 3, df = 29)	-0.44 4 (P = 0 : 14 (P = = 1 (P = Othe Mean -0.7 -2.26 -1.17 -0.31 -0.54 -1.2 7 (P = 0 4.63 -0.28 1 (P = 0	1.63 .28); ² = 0.03); PT OALE SD 1.47 1.45 0.84 1.28 1.28 1.28 1.28 1.28 1.47 1.29; ² 1.99 1 .14); ²	$\begin{array}{c} 36\\ 278\\ =218\\ =21\%\\ 442\\ ^2=28\\ ^2=7\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	8.8% 41.6% 100.0% 7.6% Weight 8.0% 4.9% 5.0% 5.1% 2.1% 8.3% 10.0%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random. 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62] -0.44 [-0.78, -0.10]	Mean Difference IV. Random. 95% Cl	mmol/L +2 Trols
с	Kwak 2020 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect Total (95% CI) Heterogeneity: Tau ² = Test for overall effect Test for subgroup 1.3.1 SU He 2013 Kim 2013 Kim 2013 Kim 2013 Kim 2016 Park 2017-set Kim 2017b Suzuki 2018 Vulana 2016 Park 2017-set Kim 2017b Suzuki 2018 Vulana 2016 Park 2017-set Kim 2017b Suzuki 2018 Vulana 2016 Heterogeneity: Tau ² = Test for overall effect: 1.3.3 GLT2 inhibitor 1.3.3 GLT2 inhibitor Fuchigam 2020 Kiwak 2020	0.04; Cf Z = 2.35 0.07; Cf Z = 5.22 rences: DPPPA Mean 3.24 -1.2 -3.64 -2.33 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.54 0.058; Cf Z = 5.70 rs -1.27 -1.51	$\begin{array}{l} 1.42\\ i^2=5.00\\ (P=0.)\\ (P=0.)\\ (P=0.)\\ (P<0.)\\ (P<0.)\\ (P<0.)\\ (P<0.)\\ (P=0.)\\ (P<0.)\\ 1.01\\ $	34 34 269 269 269 269 269 269 269 269	-0.44 4 (P = 0 = 1 (P = 0 Otho Mean 3.83 -0.7 -2.26 Mean -0.54 -1.17 -0.31 -0.54 -1.2 7 (P = 0 4.63 -0.28 1 (P = 0	1.63 .28); ² = 0.03); er OAE SD 1.47 1.45 1.28 1.28 1.28 1.28 1.47 1.63 2.3 1.99 1 .14); ² 1.59 1.63	$\begin{array}{c} 36\\ 278\\ =21\%\\ 442\\ ^2=21\\ ^2=7\\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 4.8% 5.0% 3.14.0% 4.8% 5.5.1% 2.1% 8.3% 10.4%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62] -0.74 [-2.11, 0.62] -0.74 [-2.11, 0.62]	Mean Difference IV. Random. 95% Cl	mmol/L + zols
с	Kwak 2020 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for overall effect: tau ² = Test for overall effect: tau He 2013 Kim 2013 Kim 2013 Kim 2013 Kim 2016 Park 2017-gem Park 2017-gem Park 2017-gem Park 2017-get Park 2017-get Park 2017-sit Kim 2017b Suzuki 2018 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.3.3 SGLT2 inhibitor Fuchigami 2020 Kwak 2020 Subbtai (95% CI)	0.04; Cr Z = 2.35 0.07; Cr Z = 5.22 rences: ppP4 Mean 3.24 -3.64 -1.2 -3.64 -1.2 -2.33 -2.33 -2.33 -1.32 -2.33 -1.32 -1.02 -1.4 0.00; Cr Z = 5.70 4.83 -1.54 0.58; Cr Z = 1.07 rs -1.27 -	1.42 $i^2 = 5.06$ (P = 0.0) $i^2 = 19.9, 0$ (P < 0.0) (P < 0.0) (P < 0.0) (P < 0.0) 1.01 1.63 1.61 1.61 1.78 1.64 2.19 1.21 $i^2 = 6.43$ (P < 0.0) 1.21 $i^2 = 2.20$ (P < 0.0) 1.54 1.42 1.54 1.42	34 34 269 269 22) 461 48, df =)0001) 4.6. df 0005 7 24 162 23 23 23 23 19 167 3, df = 29) 163 34 19 163 34 19 163 34 19 163 34 19 163 34 19 163 163 163 163 163 163 163 163	-0.44 4 (P = 0 14 (P = 14 (P = 0 the Mean 3.83 -0.7 -2.26 -1.17 -1.17 -0.31 -0.54 -1.2 7 (P = 0 4.63 -0.28 1 (P = 0 -0.83 -0.44 1 (P = 0 -0.83 -0.44	1.63 .28); ² = 0.15) = 0.03) r OAL SD 1.47 1.45 1.28 1.28 1.28 1.28 1.28 1.28 1.28 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.45 1.47 1.47 1.45 1.47 1.47 1.45 1.47 1.47 1.45 1.47 1.47 1.45 1.47 1.47 1.45 1.47 1.59 1.53 1.27 1.57	$\begin{array}{c} 36\\ 278\\ 278\\ =21\%\\ 442\\ ^2=21\\ ^2=7\\ \hline \\ 12\\ 17\\ 18\\ 24\\ 17\\ 18\\ 24\\ 17\\ 18\\ 10\\ 26\\ 18\\ 138\\ =0\%\\ 11\\ 15\\ 26\\ 26\\ 26\\ 168\\ 36\\ 204\\ 204\\ 204\\ 204\\ 204\\ 204\\ 204\\ 204$	8.8% 41.6% 100.0% 3% 7.6% Weight 8.0% 5.0% 14.0% 5.0% 3.1% 5.5.1% 2.1% 8.3% 10.4% 24.3% 10.1% 34.4%	-1.07 [-1.70, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] -0.59 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62] -0.74 [-2.11, 0.62] -0.74 [-2.11, 0.62] -0.74 [-2.7, -0.35] -0.67 [-1.27, -0.35]	Mean Difference IV. Random. 95% Cl	mmol/L 2 rols
С	Kwak 2020 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for overall effect: Test for suboroup diffe Study or Subgroup 1.3.1 SU He 2013 Kim 2013 Kim 2013 Kim 2013 Kim 2013 Subtal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.3.3 GLT2 inhibitor Fuchgami 2020 Kwak 2020 Subtal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.3.3 SGLT2 inhibitor Fuchgami 2020 Kwak 2020 Subtal (95% CI)	0.04; Cr 2 = 2.35 0.07; Cr 2 = 5.23 0.07; Cr 2 = 5.22 pPP44 Mean 3.24 -1.2 -3.64 -1.2 -3.64 -1.2 -3.64 -1.2 -1.3 -1.2 -1.54 0.58; Cr 2 = 1.07 rs -1.27 -1.51 0.12; Cr 2 = 2.21 0.07; Cr 2 = 5.25 -1.27 -1.51 -1.57 -1.27 -1.57 	$\begin{array}{l} 1.42\\ i^2=5.06\\ (P=0.0)\\ i^2=19.0, choose \\ P=0.0\\ (P<0.0)\\ (P<0.0)\\ (P<0.0)\\ (P<0.0)\\ (P<0.0)\\ (P<0.0)\\ (P<0.0)\\ 1.01\\ 1.83\\ 1.64\\ 1.01\\ 1.88\\ 1.64\\ 2.1\\ 1.78\\ 1.64\\ 2.1\\ 1.78\\ 1.64\\ 2.1\\ 1.78\\ 1.64\\ 1.17\\ 1.78\\ 1.64\\ 1.17\\ 1.78\\ 1.64\\ 1.17\\ 1.78\\ 1.64\\ 1.17\\ 1.78\\ 1.64\\ 1.17\\ 1.78\\ 1.64\\ 1.17\\ 1.78\\ 1.$	34 34 269 269 22) 461 18, df = 100001 00001 00001 100001 24 16 23 23 23 19 17 26 23 29 167 3, df = 29) 163 34 197 163 34 197 167 17 163 34 197 167 17 167 17 167 17 167 17 17 167 17 17 17 17 17 17 17 17 17 1	-0.44 4 (P = 0 14 (P = 0 the Mean 3.83 -0.7 -2.26 -1.17 -0.31 -0.54 -1.2 7 (P = 0 4.63 -0.28 1 (P = 0 -0.83 -0.44 1 (P = 0	1.63 .28); ² = 0.15) = 0.03) or OAE SD 1.47 1.45 1.28 1.47 1.63 2.3 .49); ² 1.47 1.63 1.47 1.63 1.47 1.49 1.47 1.59 1.63 .12); ²	$\begin{array}{r} 36\\ 278\\ 278\\ 278\\ 278\\ 28\\ 28\\ 28\\ 28\\ 28\\ 28\\ 28\\ 28\\ 28\\ 2$	8.8% 41.6% 100.0% 3% X.6% Weight 8.0% 14.0% 4.8% 5.0% 3.1% 5.5.1% 2.1% 8.3% 10.4% 2.4.3% 10.1% 3.4.4%	-1.07 [-1.70, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] -0.59 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62] -0.74 [-2.11, 0.62] -0.44 [-0.78, -0.10] -1.07 [-1.79, -0.35] -0.67 [-1.27, -0.08]	Mean Difference IV. Random. 95% Cl	mmol/L 2 rols
С	Kwak 2020 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for overall effect: Test for overall effect: Test for suborou diffe Study or Subgroup 1.3.1 SU Heterogeneity: Tau ² = Test for overall effect: 1.3.2 Glinide Ando 2014 Osonoi 2014 Subbtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.3.3 GLT2 inhibitor Fuchigami 2020 Subtai (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.3.3 GLT2 inhibitor Fuchigami 2020 Subtai (95% CI)	0.04; Crt Z = 2.35 0.07; Cr Z = 2.35 0.07; Cr Z = 5.22 DPP4 -1.2 -3.64 -1.32 -3.64 -2.33 -2.33 -2.33 -2.33 -1.32 -1.02 -1.4 0.00; Cr Z = 5.70 -1.51 0.05; Cr Z = 2.21	1.42 i ² = 5.00 (P = 0.0 (P = 0.0 (P < 0.0 Chi ² = 19.4 (P < 0.0 Chi ² = 4 inhibit <u>SD</u> 1.47 0.94 1.61 1.78 2.19 1.64 2.19 1.21 i ² = 6.42 (P = 0.0 1.54 1.42 (P = 0.0 1.42 (P = 0.0 1.44 (P = 0.0 1.44 (P = 0.0 1.42 (P = 0.0 1.44 (P = 0.0 (P	34 34 269 26, df = 22) 461 18, df = 00001) .4.6. df 00001) .4.6. df 100001) 14 163 23 19 167 26 19 167 3, df = 29) 163 347 19 163 347 19 389	-0.44 4 (P = 0 = 1 (P = 0 0th Mean 3.83 -0.7 -2.26 -1.17 -1.17 -0.31 -0.54 -1.27 7 (P = 0 4.63 -0.28 1 (P = 0 -0.83 -0.44 1 (P = 0 -0.44 -0.45 -0.44 -0.28 -0.44 -0.45 -0.44 -0.45 -0.44 -	1.63 .28); ² = 0.15) or OALE SD 1.47 1.45 1.28 1.28 1.47 1.45 1.28 1.47 1.45 1.28 1.47 1.45 1.28 1.47 1.59 1.47 1.59 1.63 .12); ²	$\begin{array}{r} 36\\ 278\\ 278\\ =21\%\\ 442\\ l^2=21\\ l^2=7\\ r\\ r\\$	8.8% 41.6% 100.0% 7.6% Weight 8.0% 7.6% 8.0% 7.2% 3.1% 7.2% 3.1% 14.0% 2.1% 8.3% 10.4%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.96, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -0.91 [-1.22, -0.60] 0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62] -0.74 [-2.11, 0.62] -0.74 [-2.11, 0.62] -0.67 [-1.27, -0.08] -0.80 [-1.06, -0.54]	Mean Difference IV. Random. 95% Cl	mmol/L
С	Kwak 2020 Subbtai (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Total (95% Cl) Heterogeneily: Tau ² = Test for overall effect: Test for suborou diffe Heterogeneily: Tau ² = Study or Subgroup 1.3.1 SU Heterogeneily: Tau ² = Test for verall effect: 1.3.2 Glinide Ando 2014 Osonoi 2014 Subtotal (95% Cl) Heterogeneily: Tau ² = Test for verall effect: 1.3.3 SGLT2 inhibitor Fuckjagmi 2020 Kwak 2020 Subtotal (95% Cl) Heterogeneily: Tau ² = Test for verall effect: Total (95% Cl) Heterogeneily: Tau ² = Test for verall effect:	0.04; Cr Z = 2.35 0.07; Cr Z = 5.25 memory 2 = 5.22 memory 2 = 5.22 memory 2 = 5.22 memory 2 = 5.22 -1.02 -1.32 -	1.42 $i^2 = 5.00$ (P = 0.1) $i^2 = 19.4$ (P = 0.1) (P = 0.1) (P = 0.1) 1.47 0.94 1.61 1.61 1.63 1.64 2.19 1.29 1.29 1.54	34 269 269 36, df = - 122) 461 148, df = 00001) .46. df rors Total 24 16 23 23 19 17 26 19 10 77 26 19 10 77 26 19 10 77 26 19 10 77 26 10 10 10 10 10 10 10 10 10 10	-0.44 4 (P = 0 1 (P = 1) 1 (P = 1) 1 (P = 0 1 (P = 0) 1 (P = 0) 4.63 -0.28 1 (P = 0) -0.83 -0.44 1 (P = 0) -0.84 -0.44 1 (P = 0) -0.83 -0.44 1 (P = 0) -0.83 -0.44 -0.84	1.63 .28); ² = 0.15) Pr OALE SD 1.47 1.45 0.84 1.28 1.28 1.23 .49); ² 1.99 1.47 1.59 1.63 .12); ² = 0.23)	$\begin{array}{c} 366\\ 278\\ 278\\ =21\%\\ 442\\ I^2=20\\ I^2=7\\ 7\\ 18\\ 9\\ 9\\ 17\\ 26\\ 18\\ 138\\ =0\%\\ 11\\ 15\\ 26\\ =55\%\\ 168\\ 36\\ 204\\ =59\%\\ 368\\ I^2=2\\ \end{array}$	8.8% 41.6% 100.0% 7.6% Weight 8.0% 14.0% 5.0% 2.1% 8.3% 10.1% 2.1% 8.3% 10.1% 2.4.3% 2.4.3% 10.1% 2.4.4%	-1.07 [-1.79, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random <u>95% C1</u> -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -1.16 [-2.28, -0.04] -1.02 [-1.62, 1.22] -0.91 [-1.22, -0.60] 0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62] -0.44 [-0.78, -0.10] -1.07 [-1.79, -0.35] -0.67 [-1.27, -0.08] -0.80 [-1.06, -0.54]	Mean Difference IV. Random. 95% Cl	mmol/L
c	Kwak 2020 Subbtal (95% CI) Heterogeneily: Tau ² = Test for overall effect: Total (95% CI) Heterogeneily: Tau ² = Test for overall effect: Test for suborou diffe Heterogeneily: Tau ² = Study or Subgroup 1.3.1 SU Heterogeneily: Tau ² = Test for overall effect: 1.3.2 Glinide Ando 2014 Osubtotal (95% CI) Heterogeneily: Tau ² = Test for overall effect: 1.3.3 SGLT2 inhibitor Tuchigami 2020 Kwak 2020 Subtotal (95% CI) Heterogeneily: Tau ² = Test for overall effect: Total (95% CI)	0.04; Cr Z = 2.35 0.07; Cr Z = 2.35 0.07; Cr Z = 5.22 rences: DPP4 Maan 3.24 -1.22 -3.64 -2.33 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.32 -1.54 0.05; Cr Z = 1.27 -1.51 0.12; Cr Z = 2.21 0.04; Cr Z = 2.35 -1.27 -1.51 0.12; Cr Z = 2.35 -1.27 -1.51 -1.51 -1	1.42 $i^2 = 5.00$ (P = 0.1) (P = 0.1) (P < 0.1) 1.47 0.94 1.61 1.83 1.64 2.11 $i^2 = 6.42$ (P < 0.1) (P < 0.1)	34 34 269 36, df = . 12) 461 18, df = 100001 18, df = 100001 24 163 23 23 23 23 23 24 163 23 23 23 26 163 34 197 1, df = . 29) 163 34 197 1, df = . 29) 163 34 197 365 197 107 107 107 107 107 107 107 10	-0.44 4 (P = 0 1 (P = 1) 1 (P = 1) 0 the Mean 3.83 -0.7 -2.26 0 the Mean -0.54 -1.17 -0.31 -0.54 -1.2 7 (P = 0) 4.63 -0.28 1 (P = 0) -0.83 -0.44 1 (P = 0) -0.83 -0.44 1 (P = 0) -0.83 -0.44 1 (P = 0) -0.83 -0.44 -1.12 -0.83 -0.44 -1.12 -0.83 -0.44 -1.12 -0.83 -0.44 -1.12 -0.83 -0.44 -1.12 -0.83 -0.44 -0.83 -0.44 -0.83 -0.44 -0.83 -0.44 -0.83 -0.44 -0.83 -0.44 -0.83 -0.44 -0.83 -0.44 -0.83 -0.44 -0.83 -0.44 -0.84 -0.83 -0.44 -0.8	1.63 .28); ² = 0.15) r OAL sD 1.47 1.45 0.84 1.28 1.29 1.47 1.45 1.47 1.45 1.47 1.63 1.47 1.63 1.47 1.63 1.49 1.59 1.63 .129 1.59 1.63 .129 .129 .129 1.63 .129	${}^{366}_{278}$ = 21% ${}^{442}_{2}$ = 21% ${}^{12}_{2}$ = 21% ${}^{12}_{2}$ = 21% ${}^{12}_{2}$ = 21% ${}^{12}_{2}$ = 7% ${}^{13}_{18}$ = 7% ${}^{12}_{18}$ = 7% ${}^{12}_{18}$ = 7% ${}^{12}_{18}$ = 7% ${}^{12}_{18}$ = 0% 111 15 26 204 204 204 204 204 204 204 204 204 204	8.8% 41.6% 100.0% 7.6% Weight 8.0% 4.9% 5.0% 3.1% 5.5.1% 2.1% 8.3% 10.4% 2.4.3% 10.1% 3.4.4%	-1.07 [-1.76, -0.35] -0.43 [-0.79, -0.07] -0.69 [-0.95, -0.43] Fa Mean Difference IV. Random, 95% CI -0.59 [-1.42, 0.24] -0.50 [-1.33, 0.33] -1.38 [-1.95, -0.81] -1.16 [-2.27, -0.05] -1.01 [-2.11, 0.09] -0.48 [-1.37, 0.41] -0.20 [-1.55, 1.95] -1.26 [-2.07, -0.45] -0.74 [-2.11, 0.62] -0.74 [-2.11, 0.62] -0.44 [-0.76, -0.10] -1.07 [-1.79, -0.35] -0.67 [-1.27, -0.08] -0.80 [-1.06, -0.54]	Mean Difference IV. Random. 95% Cl	mmol/L + 2 rols mmol/L + 4 Tois

FIGURE 2

Forest plots for the meta-analysis comparing the influence of DPP4 inhibitors on MAGE with other OADs in T2DM patients with no concurrent insulin therapy; (A), forest plots for the overall meta-analysis; B), forest plots for the subgroup analysis according to the control OADs; and (C), forest plots for the subgroup analysis according to the individual OAD class of controls.

	Datasets	MD (95% CI)	P for subgroup effect	I^2	P for subgroup difference
Design					
Crossover	3	-0.35 [-1.03, 0.33]	0.31	0%	
Parallel group	12	-0.74 [-1.04, -0.45]	< 0.001	38%	0.30
Patient number					
≤ 35	9	-0.74 [-1.09, -0.39]	< 0.001	0%	
> 35	6	-0.66 [-1.09, -0.23]	0.003	59%	0.78
Mean age (years)					
≤ 58	7	-0.63 [-1.06, -0.19]	0.005	0%	
> 58	8	-0.72 [-1.08, -0.36]	< 0.001	51%	0.74
Male (%)					
≤ 65	7	-0.57 [-0.98, -0.16]	0.006	51%	
> 65	7	-0.89 [-1.24, -0.54]	< 0.001	0%	0.25
Baseline HbA1c (%)					
≤ 7.5	7	-0.60 [-1.13, -0.07]	0.03	55%	
> 7.5	8	-0.62 [-0.87, -0.37]	< 0.001	0%	0.94
T2DM duration (years)					
≤ 5	5	-1.16 [-1.54, -0.79]	< 0.001	0%	
> 5	6	-0.48 [-0.75, -0.22]	< 0.001	0%	0.004
Background treatment					
Drug naïve	5	-0.52 [-1.02, -0.02]	0.04	16%	
With OAD	8	-0.80 [-1.19, -0.41]	< 0.001	57%	
Drug naïve or with OAD	2	-0.67 [-1.27, -0.08]	0.03	59%	0.69
Treatment duration (days)					
≤ 28	6	-0.62 [-1.02, -0.23]	0.002	0%	
> 28	9	-0.74 [-1.11, -0.37]	< 0.001	48%	0.68
CGM/FGM time (hours)					
24 or 48	8	-0.41 [-0.66, -0.15]	0.002	0%	
72	7	-1.05 [-1.37, -0.73]	< 0.001	5%	0.002
Quality score					
3	7	-0.67 [-1.14, -0.20]	0.005	34%	
4	4	-0.70 [-1.33, -0.07]	0.03	53%	
5	4	-0.55 [-0.84, -0.25]	< 0.001	0%	0.85

TABLE 3 Subgroup analysis for comparing DPP4 inhibitors with other OADS on MAGE.

DPP4, dipeptidyl-peptidase 4; HbA1c, glycosylated hemoglobin; T2DM, type 2 diabetes mellitus; OAD, oral antidiabetic drug; MAGE, mean amplitude of glycemic excursions; MD, mean difference; CI, confidence interval; CGM, continuous glucose monitoring; FGM, flash glucose monitoring.

symmetrical, suggesting a low risk of publication bias (Figure 3). The results of Egger's regression tests also suggested a low risk of publication bias (P = 0.301).

Discussion

In this meta-analysis, by pooling the results of 14 RCTs, we found that DPP4 inhibitors were more effective than other OADs in attenuating glycemic variability in T2DM patients without concurrent insulin treatment, as evidenced by more significantly reduced MAGE after treatment with DPP4 inhibitors. The results of sensitivity analysis by excluding one dataset at a time showed consistent results, reflecting the stability of the findings. Interestingly, the results of subgroup analyses suggested that DPP4 inhibitors were more effective in reducing MAGE compared to insulin secretagogues and nonsecretagogues, as well as compared to sulfonylureas and SGLT-2 inhibitors, in patients with T2DM duration \leq 5 years as compared to those with disease duration > 5 years, and in studies with 72 hours of glucose monitoring for MAGE measurement as compared to those with 24 or 48 hours. Taken together, this meta-analysis confirmed that DPP4 inhibitors may significantly reduce glycemic variability as evidenced by MAGE in T2DM patients with no concurrent insulin treatment.

Currently, a number of parameters have been applied to evaluate the extent of glycemic variability. Among them, time in target range (TIR) is a new vital index of glycemic control that was recently proposed to describe the percentage of time when



glucose values fall within the target range (the common default range of 3.9-10 mmol/L) in 24 h (40). Although this index is highly recommended by the American Diabetes Association (ADA) guidelines because TIR can not only be used to assess blood glucose fluctuation but also be used as a glycemic target besides HbA1c, studies using this parameter to evaluate the effect of anti-diabetic drugs on glycemic variability are still emerging (41). MAGE was considered as a gold standard for assessing the short-term within-day glycemic variability (GV), so that a large number of high-quality studies that used MAGEs for the evaluation of glucose fluctuation have been performed (42, 43). Previous studies showed that MAGE is independent of mean glycemic level (42) and associated with higher circulating insulin antibody (44), which may provide additional information for the evaluation and management of patients with T2DM (45). A cross-sectional study including 288 Chinese T2DM patients suggested that MAGE was better associated with vascular outcomes including coronary artery disease (CAD), stroke, and chronic kidney disease (CKD) than other indices of glycemic variability (46). Besides, previous studies showed that high MAGE was an independent predictive factor of poor prognosis in patients with CAD (9), including acute coronary syndrome (47, 48), and an early study showed that glycemic variability expressed as the MAGE was significantly associated with coronary plaque rupture in patients with acute myocardial infarction (AMI) (49). In addition, it was shown that high MAGE level was significantly associated with incidence of major adverse cardiovascular events after AMI (50). Similarly, in T2DM patients with acute ischemic stroke, MAGE was shown to be a predictor of early neurological deterioration (51). However, to the best of our knowledge, a clinically significant change margin of MAGE in patients with T2DM remains unknown, which needs more studies to investigate in

the future. In addition, increased glycemic fluctuation is just one of the potential factors to the incidence of MACE in CVOTS. Nearly all CVOTs conducted with DPP4 inhibitors so far have demonstrated a neutral effect on MACE (52–56).

To the best of our knowledge, there is only one meta-analytic study that evaluated the influences of DPP4 inhibitors on glycemic variability compare to other OADs (35). This study included seven RCTs before 2018 and concluded that DPP4 inhibitors may be more effective than other OADs in reducing MAGE. The limited number of available datasets prevented the authors from performing further subgroup analyses. Moreover, the previous meta-analysis included a study with a methodological flaw in randomization (57), which significantly confounded the results of the meta-analysis. Compared to the previous meta-analysis, the strengths of the current metaanalysis include the rigorous literature search, strict inclusion and exclusion criteria, and performance of multiple sensitivity analysis to confirm the stability and robustness of the findings. We included 14 RCTs with 855 patients with T2DM, which was much larger than the previous meta-analysis (279 patients). The results suggested that DPP4 inhibitors are more effective than other OADs at attenuating glycemic variability in T2DM patients with no concurrent insulin therapy. This is of clinical importance. The available OADs for patients with T2DM have increased in recent decades. Although these OADs all have glucose-lowering efficacy, some may provide additional benefits for T2DM patients. In view of the potential role of increased glycemic variability in the pathogenesis of vascular complications in T2DM (12), agents that reduce glycemic variability may further improve the prognosis of T2DM patients.

The specific multidimensional mechanisms of DPP4 inhibitors for glycemic regulation, such as enhancing incretin preservation and inhibiting glucagon production (18, 19), may

be the key reason that DPP4 inhibitors are more effective than other OADs in reducing MAGE. Further subgroup analysis according to individual OAD categories for the control showed that DPP4 inhibitors were more effective than SUs at reducing MAGE, whereas DPP4 inhibitors were comparable to glinides at reducing MAGE. This is consistent with previous observations that SUs are associated with higher glycemic fluctuation in T2DM patients (58). Moreover, glinides are short-acting insulin secretagogues and generally administered three times daily, which is also shown to be associated with reduced glucose fluctuation as compared with Sus (59). Interestingly, we also found that DPP4 inhibitors are more effective than SGLT-2 inhibitors in reducing MAGE. Of note, two of the included studies with SGLT-2 inhibitors as controls both used dapagliflozin. A recent experimental study in high-fat, high-sucrose diet mice showed that dapagliflozin increased plasma glucagon levels during acute declines in blood glucose (60), which may lead to increased glycemic fluctuation. Since only two RCTs were included in the subgroup of SGLT-2 inhibitors, further studies are needed to validate the findings and clarify the possible mechanisms underlying the superiority of DPP4 inhibitors to SGLT-2 inhibitors on MAGE.

Subgroup analysis also suggested that the reduction of MAGE was more remarkable in patients with T2DM duration \leq 5 years as compared to those with disease duration > 5 years. Patients with longer T2DM duration are likely to have increased glycemic fluctuation severity, which is likely correlated with impaired pancreatic beta-cell function in these patients (61). Subsequently, the severe glycemic dysregulation in patients with long T2DM duration challenges hypoglycemic treatment to minimize glycemic fluctuations. In addition, a more remarkable reduction in MAGE after DPP4 inhibitor treatment was shown in studies with glucose monitoring for 72 hours as compared to those with 24 or 48-hour monitoring. These results indicate that the improvement of glycemic variability by DPP4 inhibitors was even more remarkable with a relatively longer monitoring duration.

This study also has limitations that should be considered when the results are interpreted. Firstly, there remains no consensus regarding the optimal parameter for measuring glycemic variability in T2DM patients. The influence of DPP4 inhibitors on other glycemic variability parameters in T2DM patients, such as TIR, should be evaluated. Besides, GV was analyzed based on CGM with relatively short durations among the included studies (24~72 hours). Parameters of GV calculated on the basis of CGM with longer duration (e.g., 14 days) may more accurately reflect the severity of glucose fluctuation. In addition, this meta-analysis was based on data at the study level rather than individual patients. Therefore, the results of subgroup analysis should be interpreted with caution. Largescale RCTs or meta-analysis based on individual patient data may be considered to confirm whether patient characteristics or concurrent medications influence the potential effect of DPP4 inhibitors on MAGE. Finally, nine of the 14 RCTs included in the meta-analysis used insulin secretagogues (mostly SUs) as controls. None of the included studies compared DPP-4 inhibitors with the oral formulation of the GLP-1 receptor agonist semaglutide on GV. Studies are warranted for further investigation and the conclusion that DPP-4 inhibitors may be more effective than other OADs in reducing GV should be interpreted with caution in this regard.

Conclusions

In conclusion, the results of the meta-analysis showed that DPP4 inhibitors may be more effective than other OADs in attenuating glycemic variability in T2DM patients receiving no concurrent insulin therapy.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author contributions

SC, RZ, RC, YZ and MY conceived and designed research; SC and RZ collected data and conducted research; SC and MY performed or supervised analyses; SC, RZ, YMZ, SR and MY interpreted data; SC wrote the initial paper. All authors provided substantive suggestions for revision, reviewed and approved final version of the paper, and for all aspects of the work in ensuring that questions related to the accuracy.

Funding

This study received funding from MSD China Holding Co. Ltd. for funding editorial assistance, which assistance was provided by Medjaden Inc.

Acknowledgments

Jingya Chen of MSD China Holding Co., Ltd., Shanghai, China, assisted literature research of the manuscript. Administrative assistance was provided by Li Qi of MSD China Holding Co., Ltd., Shanghai, China. Medical writing and editorial assistance was provided by Medjaden Inc. This assistance was funded by MSD China.

Conflict of interest

SC, RZ, YZ and YMZ are employees of MSD China; SR is employee of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway NJ, US. This study received funding from MSD China. The funder had the following involvement with the study: study design, data collection and analysis, and preparation of the manuscript. All authors declare no other competing interests.

The remaining authors declare that the research was conducted in the absence of any commercial or financial

References

1. Maranta F, Cianfanelli L, Cianflone D. Glycaemic control and vascular complications in diabetes mellitus type 2. *Adv Exp Med Biol* (2021) 1307:129–52. doi: 10.1007/5584_2020_514

2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* (2018) 14:88–98. doi: 10.1038/nrendo.2017.151

3. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). *Diabetes Care* (2020) 43:487–93. doi: 10.2337/ dci19-0066

4. Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuniga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. *BMJ* (2019) 367:15887. doi: 10.1136/bmj.15887

5. Rodbard D. Glucose variability: A review of clinical applications and research developments. *Diabetes Technol Ther* (2018) 20:S25–S215. doi: 10.1089/dia.2018.0092

6. Nusca A, Tuccinardi D, Albano M, Cavallaro C, Ricottini E, Manfrini S, et al. Glycemic variability in the development of cardiovascular complications in diabetes. *Diabetes Metab Res Rev* (2018) 34:e3047. doi: 10.1002/dmrr.3047

7. Kovatchev B. Glycemic variability: Risk factors, assessment, and control. J Diabetes Sci Technol (2019) 13:627–35. doi: 10.1177/1932296819826111

8. Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, et al. Long-term glycemic variability and risk of adverse outcomes: A systematic review and meta-analysis. *Diabetes Care* (2015) 38:2354–69. doi: 10.2337/dc15-1188

9. Pu Z, Lai L, Yang X, Wang Y, Dong P, Wang D, et al. Acute glycemic variability on admission predicts the prognosis in hospitalized patients with coronary artery disease: a meta-analysis. *Endocrine* (2020) 67:526-34. doi: 10.1007/s12020-019-02150-1

10. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. *Diabetes Obes Metab* (2010) 12:288–98. doi: 10.1111/j.1463-1326.2009.01160.x

11. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA* (2006) 295:1681–7. doi: 10.1001/jama.295.14.1681

12. Valente T, Arbex AK. Glycemic variability, oxidative stress and impact on complications related to type 2 diabetes mellitus. *Curr Diabetes Rev* (2021) 17(7): e071620183816. doi: 10.2174/1573399816666200716201550

13. van Genugten RE, van Raalte DH, Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. *Diabetes Obes Metab* (2012) 14:101–11. doi: 10.1111/j.1463-1326.2011.01473.x

14. Chen K, Kang D, Yu M, Zhang R, Zhang Y, Chen G, et al. Direct head-tohead comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of longterm randomized controlled trials. *Diabetes Obes Metab* (2018) 20:1029–33. doi: 10.1111/dom.13147

15. Lefebvre PJ, Paquot N, Scheen AJ. Inhibiting or antagonizing glucagon: making progress in diabetes care. *Diabetes Obes Metab* (2015) 17:720-5. doi: 10.1111/dom.12480

relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

16. Kohnert KD, Freyse EJ, Salzsieder E. Glycaemic variability and pancreatic beta-cell dysfunction. *Curr Diabetes Rev* (2012) 8:345-54. doi: 10.2174/157339912802083513

17. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. *Diabetes Care* (2012) 35:2076–82. doi: 10.2337/dc12-0199

18. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. *Endocr Rev* (2014) 35:992–1019. doi: 10.1210/er.2014-1035

19. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). *Best Pract Res Clin Endocrinol Metab* (2009) 23:479-86. doi: 10.1016/j.beem.2009.03.004

20. Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice. *Diabetes Vasc Dis Res* (2018) 15:175–84. doi: 10.1177/1479164118756240

21. He YL, Foteinos G, Neelakantham S, Mattapalli D, Kulmatycki K, Forst T, et al. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. *Diabetes Obes Metab* (2013) 15:1111–9. doi: 10.1111/dom.12146

22. Kim HS, Shin JA, Lee SH, Kim ES, Cho JH, Son HY, et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. *Diabetes Technol Ther* (2013) 15:810–6. doi: 10.1089/ dia.2013.0038

23. Ando K, Nishimura R, Seo C, Tsujino D, Sakamoto M, Utsunomiya K. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study. *Expert Opin Pharmacother* (2014) 15:2479–85. doi: 10.1517/14656566.2014.970531

24. Osonoi T, Saito M, Tamasawa A, Ishida H, Osonoi Y. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study. *Expert Opin Pharmacother* (2014) 15:1325–35. doi: 10.1517/14656566.2014.920323

25. Xiao X, Cui X, Zhang J, Han Z, Xiao Y, Chen N, et al. Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study. *Exp Ther Med* (2016) 12:3002–8. doi: 10.3892/etm.2016.3729

26. Kim G, Oh S, Jin SM, Hur KY, Kim JH, Lee MK. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus. *Expert Opin Pharmacother* (2017) 18:1179–86. doi: 10.1080/14656566.2017.1353080

27. Kim NH, Kim DL, Kim KJ, Choi KM, Baik SH, Kim SG. Effects of vildagliptin or pioglitazone on glycemic variability and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A 16-week, randomised, open label, pilot study. *Endocrinol Metab* (*Seoul*) (2017) 32:241–7. doi: 10.3803/En.M.2017.32.2.241

28. Park SE, Lee BW, Kim JH, Lee WJ, Cho JH, Jung CH, et al. Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study). *Diabetes Obes Metab* (2017) 19:892–6. doi: 10.1111/dom.12869

29. Satoh H, Ohira T, Moriya C, Inoue I, Kuribayashi S, Seino H, et al. Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial. *Diabetes Metab* (2017) 43:550–3. doi: 10.1016/j.diabet.2017.07.010

30. Suzuki R, Eiki JI, Moritoyo T, Furihata K, Wakana A, Ohta Y, et al. Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naive Japanese patients with type 2 diabetes mellitus. *Diabetes Obes Metab* (2018) 20:2274–81. doi: 10.1111/dom.13364

31. Vianna AGD, Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Faria-Neto JR. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes. *Diabetes Res Clin Pract* (2018) 139:357–65. doi: 10.1016/j.diabres.2018.03.035

32. Takahashi H, Nishimura R, Tsujino D, Utsunomiya K. Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? a randomized, cross-over, continuous glucose monitoring-based pilot study. *J Diabetes Investig* (2019) 10:714–22. doi: 10.1111/jdi.12922

33. Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). *Cardiovasc Diabetol* (2020) 19:1. doi: 10.1186/s12933-019-0977-z

34. Kwak SH, Hwang YC, Won JC, Bae JC, Kim HJ, Suh S, et al. Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study). *Diabetes Obes Metab* (2020) 22:173–81. doi: 10.1111/dom.13882

35. Lee S, Lee H, Kim Y, Kim E. Effect of DPP-IV inhibitors on glycemic variability in patients with T2DM: A systematic review and meta-analysis. *Sci Rep* (2019) 9:13296. doi: 10.1038/s41598-019-49803-9

36. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* (2009) 339: b2535. doi: 10.1136/bmj.b2535

37. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration London (2011). Available at: www.cochranehandbook.org.

38. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 21:1539–58. doi: 10.1002/sim.1186

39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* (1997) 315:629-34. doi: 10.1136/bmj.315.7109.629

40. Yoo JH, Kim JH. Time in range from continuous glucose monitoring: A novel metric for glycemic control. *Diabetes Metab J* (2020) 44:828–39. doi: 10.4093/dmj.2020.0257

41. Gabbay MAL, Rodacki M, Calliari LE, Vianna AGD, Krakauer M, Pinto MS, et al. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes. *Diabetol Metab Syndr* (2020) 12:22. doi: 10.1186/s13098-020-00529-z

42. Monnier L, Colette C, Owens DR. The application of simple metrics in the assessment of glycaemic variability. *Diabetes Metab* (2018) 44:313–9. doi: 10.1016/j.diabet.2018.02.008

43. Verges B, Pignol E, Rouland A, Bouillet B, Baillot-Rudoni S, Quilot E, et al. Glycemic variability assessment with a 14-day continuous glucose monitoring system: When and how long to measure MAGE (Mean amplitude of glucose excursion) for optimal reliability? *J Diabetes Sci Technol* (2022) 16(4):982–7. doi: 10.1177/1932296821992060

44. Zhu J, Yuan L, Ni WJ, Luo Y, Ma JH. Association of higher circulating insulin antibody with increased mean amplitude glycemic excursion in patients with type 2 diabetes mellitus: A cross-sectional, retrospective case-control study. *J Diabetes Res* (2019) 2019:7304140. doi: 10.1155/2019/7304140

45. Monnier L, Colette C, Owens DR. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. *Diabetes Metab Res Rev* (2009) 25:393–402. doi: 10.1002/dmrr.962

46. Tong L, Chi C, Zhang Z. Association of various glycemic variability indices and vascular outcomes in type-2 diabetes patients: A retrospective study. *Med (Baltimore)* (2018) 97:e10860. doi: 10.1097/MD.00000000010860

47. Takahashi H, Iwahashi N, Kirigaya J, Kataoka S, Minamimoto Y, Gohbara M, et al. Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. *Cardiovasc Diabetol* (2018) 17:116. doi: 10.1186/s12933-018-0761-5

48. Su G, Zhang T, Yang H, Dai W, Tian L, Tao H, et al. Admission glycemic variability correlates with in-hospital outcomes in diabetic patients with non-ST segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. *Anatol J Cardiol* (2018) 19:368–73. doi: 10.14744/AnatolJCardiol.2018.47487

49. Teraguchi I, Imanishi T, Ozaki Y, Tanimoto T, Orii M, Shiono Y, et al. Impact of glucose fluctuation and monocyte subsets on coronary plaque rupture. *Nutr Metab Cardiovasc Dis* (2014) 24:309–14. doi: 10.1016/j.numecd.2013.08.010

50. Su G, Mi SH, Tao H, Li Z, Yang HX, Zheng H, et al. Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. *Diabetes Care* (2013) 36:1026–32. doi: 10.2337/dc12-0925

51. Hui J, Zhang J, Mao X, Li Z, Li X, Wang F, et al. The initial glycemic variability is associated with early neurological deterioration in diabetic patients with acute ischemic stroke. *Neurol Sci* (2018) 39:1571–7. doi: 10.1007/s10072-018-3463-6

52. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med* (2013) 369:1327–35. doi: 10.1056/NEJM0a1305889

53. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* (2013) 369:1317–26. doi: 10.1056/NEJMoa1307684

54. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med* (2015) 373:232–42. doi: 10.1056/NEJMoa1501352

55. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. *JAMA* (2019) 321:69–79. doi: 10.1001/jama.2018.18269

56. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. *Jama* (2019) 322:1155–66. doi: 10.1001/jama.2019.13772

57. Park KS, Kwak S, Cho YM, Jang HC, Kim SY, Jung HS. Vildagliptin reduces plasma stromal cell-derived factor-1alpha in patients with type 2 diabetes compared with glimepiride. J Diabetes Investig (2017) 8:218–26. doi: 10.1111/jdi.12572

58. Yoo S, Chin SO, Lee SA, Koh G. Factors associated with glycemic variability in patients with type 2 diabetes: Focus on oral hypoglycemic agents and cardiovascular risk factors. *Endocrinol Metab (Seoul)* (2015) 30:352–60. doi: 10.3803/EnM.2015.30.3.352

59. Omori K, Nomoto H, Nakamura A, Takase T, Cho KY, Ono K, et al. Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. *J Diabetes Investig* (2019) 10:367–74. doi: 10.1111/jdi.12889

60. Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E, et al. SGLT1 in pancreatic alpha cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. *Mol Metab* (2019) 19:1–12. doi: 10.1016/j.molmet.2018.10.009

61. Takai M, Anno T, Kawasaki F, Kimura T, Hirukawa H, Mune T, et al. Association of the glycemic fluctuation as well as glycemic control with the pancreatic beta-cell function in Japanese subjects with type 2 diabetes mellitus. *Intern Med* (2019) 58:167–73. doi: 10.2169/internalmedicine.1053-18